Market Research Report
Global Oncology Biosimilars Market 2016-2020
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||319672|
|Published||Content info||109 Pages
|Global Oncology Biosimilars Market 2016-2020|
|Published: February 17, 2016||Content info: 109 Pages||
Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes.
Technavio's analysts forecast the global oncology biosimilars market to grow at a CAGR of 31.76% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global oncology biosimilars market for the period 2016-2020. To calculate the market size, the report considers revenue generated from the sales of biosimilars used to treat cancer.
The market is divided into the following segments based on geography:
Technavio's report, Global Oncology Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.